Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)

Dihexa represents one of the most promising and most uncertain compounds in the nootropic space. It was developed at Washington State University in Dr. Joseph Harding's laboratory, which spent decades studying the angiotensin IV/AT4 receptor system's role in cognition. The backstory matters. Angiotensin IV, a metabolite of the blood pressure hormone angiotensin II, was found to enhance learning and memory in animals when injected into the brain. The problem was that angiotensin IV couldn't cross the blood-brain barrier when given systemically, had a very short half-life, and wasn't orally bioavailable. Harding's team set out to create an analog that could be taken orally and still reach the brain. Dihexa was the result of that medicinal chemistry effort. It's not technically a peptide but a peptidomimetic, a small molecule designed to mimic peptide activity. Its structure (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is modified enough from natural peptides that it resists enzymatic degradation and crosses the blood-brain barrier. The mechanism took an unexpected turn when the team discovered that dihexa's cognitive effects weren't primarily through the AT4 receptor. Instead, it works by binding to hepatocyte growth factor (HGF) and enhancing its interaction with the c-Met receptor. The HGF/c-Met system is a growth factor pathway involved in organ development, tissue repair, and, in the brain, synaptogenesis and neuronal survival. The cell culture data generated the headline claim. In assays measuring dendritic spine formation (a proxy for new synapse creation), dihexa was active at picomolar concentrations, while BDNF (brain-derived neurotrophic factor, the body's primary synaptogenesis signal) required nanomolar concentrations for the same effect. That's a roughly 10-million-fold potency difference in that specific assay. It's a real finding, but it's important to understand it's measuring one endpoint in a dish, not overall cognitive potency. The animal data is more directly relevant. A 2013 study in JPET (PMID: 23197775) tested dihexa in aged rats and rats with scopolamine-induced cognitive impairment. Treated animals showed restored performance on spatial memory tasks (Morris water maze, radial arm maze) compared to controls. The effects persisted after stopping dihexa, suggesting that the cognitive improvement came from structural synaptic changes rather than transient pharmacological effects. Now for the honest caveats. All the key studies come from one laboratory. Independent replication by other groups is limited. No human clinical trials have been conducted. The safety profile in humans is essentially unknown beyond anecdotal user reports. And the HGF/c-Met pathway has a dark side: it's frequently overactivated in cancer. Sustained activation of this pathway could theoretically promote tumor growth. There's no evidence this happens with short-term dihexa use, but no long-term safety studies exist to rule it out. Dihexa is not available through legitimate compounding pharmacies. It's sold by research chemical suppliers with variable quality control. Anyone considering it should understand they're taking a compound with no human clinical trial data and no pharmaceutical-grade sourcing. Dosing in the community typically ranges from 10-40 mg daily, taken orally or sublingually. These doses are extrapolated from animal study data, adjusted for body surface area. There's no validated human dosing protocol.